Cargando…
Immunogenicity and Safety of a Third COVID-19 BNT162b2 mRNA Vaccine Dose in 5- to 11-Year Olds
In this ongoing study, substantially increased ancestral SARS-CoV-2 neutralizing responses were observed 1 month after a third 10-µg BNT162b2 dose given to 5 to 11-year olds versus neutralizing responses post-dose 2. After dose 3, increased neutralizing responses against Omicron BA.1 and BA.4/BA.5 s...
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10146923/ https://www.ncbi.nlm.nih.gov/pubmed/36929216 http://dx.doi.org/10.1093/jpids/piad015 |
| _version_ | 1785034694324125696 |
|---|---|
| author | Simões, Eric A F Klein, Nicola P Sabharwal, Charu Gurtman, Alejandra Kitchin, Nicholas Ukkonen, Benita Korbal, Piotr Zou, Jing Xie, Xuping Sarwar, Uzma N Xu, Xia Lockhart, Stephen Cunliffe, Luke Lu, Claire Ma, Hua Swanson, Kena A Koury, Kenneth Shi, Pei-Yong Cooper, David Türeci, Ӧzlem Jansen, Kathrin U Şahin, Uğur Gruber, William C |
| author_facet | Simões, Eric A F Klein, Nicola P Sabharwal, Charu Gurtman, Alejandra Kitchin, Nicholas Ukkonen, Benita Korbal, Piotr Zou, Jing Xie, Xuping Sarwar, Uzma N Xu, Xia Lockhart, Stephen Cunliffe, Luke Lu, Claire Ma, Hua Swanson, Kena A Koury, Kenneth Shi, Pei-Yong Cooper, David Türeci, Ӧzlem Jansen, Kathrin U Şahin, Uğur Gruber, William C |
| author_sort | Simões, Eric A F |
| collection | PubMed |
| description | In this ongoing study, substantially increased ancestral SARS-CoV-2 neutralizing responses were observed 1 month after a third 10-µg BNT162b2 dose given to 5 to 11-year olds versus neutralizing responses post-dose 2. After dose 3, increased neutralizing responses against Omicron BA.1 and BA.4/BA.5 strains were also observed. The safety/tolerability profile was acceptable. (NCT04816643) |
| format | Online Article Text |
| id | pubmed-10146923 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Oxford University Press |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-101469232023-04-29 Immunogenicity and Safety of a Third COVID-19 BNT162b2 mRNA Vaccine Dose in 5- to 11-Year Olds Simões, Eric A F Klein, Nicola P Sabharwal, Charu Gurtman, Alejandra Kitchin, Nicholas Ukkonen, Benita Korbal, Piotr Zou, Jing Xie, Xuping Sarwar, Uzma N Xu, Xia Lockhart, Stephen Cunliffe, Luke Lu, Claire Ma, Hua Swanson, Kena A Koury, Kenneth Shi, Pei-Yong Cooper, David Türeci, Ӧzlem Jansen, Kathrin U Şahin, Uğur Gruber, William C J Pediatric Infect Dis Soc Brief Reports In this ongoing study, substantially increased ancestral SARS-CoV-2 neutralizing responses were observed 1 month after a third 10-µg BNT162b2 dose given to 5 to 11-year olds versus neutralizing responses post-dose 2. After dose 3, increased neutralizing responses against Omicron BA.1 and BA.4/BA.5 strains were also observed. The safety/tolerability profile was acceptable. (NCT04816643) Oxford University Press 2023-03-16 /pmc/articles/PMC10146923/ /pubmed/36929216 http://dx.doi.org/10.1093/jpids/piad015 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of The Journal of the Pediatric Infectious Diseases Society. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Brief Reports Simões, Eric A F Klein, Nicola P Sabharwal, Charu Gurtman, Alejandra Kitchin, Nicholas Ukkonen, Benita Korbal, Piotr Zou, Jing Xie, Xuping Sarwar, Uzma N Xu, Xia Lockhart, Stephen Cunliffe, Luke Lu, Claire Ma, Hua Swanson, Kena A Koury, Kenneth Shi, Pei-Yong Cooper, David Türeci, Ӧzlem Jansen, Kathrin U Şahin, Uğur Gruber, William C Immunogenicity and Safety of a Third COVID-19 BNT162b2 mRNA Vaccine Dose in 5- to 11-Year Olds |
| title | Immunogenicity and Safety of a Third COVID-19 BNT162b2 mRNA Vaccine Dose in 5- to 11-Year Olds |
| title_full | Immunogenicity and Safety of a Third COVID-19 BNT162b2 mRNA Vaccine Dose in 5- to 11-Year Olds |
| title_fullStr | Immunogenicity and Safety of a Third COVID-19 BNT162b2 mRNA Vaccine Dose in 5- to 11-Year Olds |
| title_full_unstemmed | Immunogenicity and Safety of a Third COVID-19 BNT162b2 mRNA Vaccine Dose in 5- to 11-Year Olds |
| title_short | Immunogenicity and Safety of a Third COVID-19 BNT162b2 mRNA Vaccine Dose in 5- to 11-Year Olds |
| title_sort | immunogenicity and safety of a third covid-19 bnt162b2 mrna vaccine dose in 5- to 11-year olds |
| topic | Brief Reports |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10146923/ https://www.ncbi.nlm.nih.gov/pubmed/36929216 http://dx.doi.org/10.1093/jpids/piad015 |
| work_keys_str_mv | AT simoesericaf immunogenicityandsafetyofathirdcovid19bnt162b2mrnavaccinedosein5to11yearolds AT kleinnicolap immunogenicityandsafetyofathirdcovid19bnt162b2mrnavaccinedosein5to11yearolds AT sabharwalcharu immunogenicityandsafetyofathirdcovid19bnt162b2mrnavaccinedosein5to11yearolds AT gurtmanalejandra immunogenicityandsafetyofathirdcovid19bnt162b2mrnavaccinedosein5to11yearolds AT kitchinnicholas immunogenicityandsafetyofathirdcovid19bnt162b2mrnavaccinedosein5to11yearolds AT ukkonenbenita immunogenicityandsafetyofathirdcovid19bnt162b2mrnavaccinedosein5to11yearolds AT korbalpiotr immunogenicityandsafetyofathirdcovid19bnt162b2mrnavaccinedosein5to11yearolds AT zoujing immunogenicityandsafetyofathirdcovid19bnt162b2mrnavaccinedosein5to11yearolds AT xiexuping immunogenicityandsafetyofathirdcovid19bnt162b2mrnavaccinedosein5to11yearolds AT sarwaruzman immunogenicityandsafetyofathirdcovid19bnt162b2mrnavaccinedosein5to11yearolds AT xuxia immunogenicityandsafetyofathirdcovid19bnt162b2mrnavaccinedosein5to11yearolds AT lockhartstephen immunogenicityandsafetyofathirdcovid19bnt162b2mrnavaccinedosein5to11yearolds AT cunliffeluke immunogenicityandsafetyofathirdcovid19bnt162b2mrnavaccinedosein5to11yearolds AT luclaire immunogenicityandsafetyofathirdcovid19bnt162b2mrnavaccinedosein5to11yearolds AT mahua immunogenicityandsafetyofathirdcovid19bnt162b2mrnavaccinedosein5to11yearolds AT swansonkenaa immunogenicityandsafetyofathirdcovid19bnt162b2mrnavaccinedosein5to11yearolds AT kourykenneth immunogenicityandsafetyofathirdcovid19bnt162b2mrnavaccinedosein5to11yearolds AT shipeiyong immunogenicityandsafetyofathirdcovid19bnt162b2mrnavaccinedosein5to11yearolds AT cooperdavid immunogenicityandsafetyofathirdcovid19bnt162b2mrnavaccinedosein5to11yearolds AT tureciözlem immunogenicityandsafetyofathirdcovid19bnt162b2mrnavaccinedosein5to11yearolds AT jansenkathrinu immunogenicityandsafetyofathirdcovid19bnt162b2mrnavaccinedosein5to11yearolds AT sahinugur immunogenicityandsafetyofathirdcovid19bnt162b2mrnavaccinedosein5to11yearolds AT gruberwilliamc immunogenicityandsafetyofathirdcovid19bnt162b2mrnavaccinedosein5to11yearolds |